| Name | Title | Contact Details |
|---|
St. Ann`s Community is Rochester`s leading senior housing and health services provider, with a tradition of quality care for older adults dating back to 1873. St. Ann`s offers a continuum of care that includes independent retirement living, assisted living, skilled nursing, memory care, short-term transitional care, palliative care, and adult day programs. One of the area`s largest employers, St. Ann`s has more than 1,200 employees who are "Caring for the Most Important People on Earth."
Hartford HealthCare is Connecticut`s most comprehensive healthcare network. With 33,000 employees and total operating revenue of $4.3 billion, Hartford HealthCare has cultivated a strong, unified culture of accountability and innovation. Its care-delivery system, serving 185 towns and cities at more than 400 locations, includes two tertiary-level teaching hospitals, an acute-care community teaching hospital, an acute-care hospital and trauma center, three community hospitals, the state`s most extensive behavioral health network, a large multispecialty physician group, a clinical care organization, a regional home care system, an array of senior care services, and a large physical therapy and rehabilitation network. Hartford HealthCare`s unique, systemwide Institute Model offers a single, high standard of care in crucial specialties at hospital and ambulatory sites across Connecticut. The institutes include: Cancer, Heart and Vascular, Neuroscience, Orthopedics and Urology.
RamSoft is a Rancho Cucamonga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Medaudit Services Inc is a Midland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.